| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 7 | -3,467,813 | 100% | $12.08 | -$41,898,701 |
| Net | -7 | -3,467,813 | -100% | -$41,898,701 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Skorpios Trust | 10%+ Owner | $39,843,046 | -$30,600,000 | -43% | 04 Jun 2025 |
| Adrian R. Krainer | Director | $11,257,458 | -$3,902,456 | -26% | 10 Mar 2026 |
| Edward M. Kaye MD | Director | $5,449,282 | -$4,320,604 | -44% | 15 Mar 2026 |
| Barry Ticho | Chief Medical Officer | $2,383,494 | -$1,214,910 | -34% | 15 Mar 2026 |
| Jonathan Allan | General Counsel & Corp Sec | $1,442,556 | -$1,520,920 | -51% | 15 Mar 2026 |
| Arthur Tzianabos | Interim Executive Chair, Director | $1,253,663 | -$174,214 | -12% | 10 Mar 2026 |
| Thomas Leggett | Chief Financial Officer | $1,012,292 | 15 Mar 2026 | ||
| Arthur A. Levin | Director | $825,111 | -$22,264 | -2.6% | 13 Mar 2026 |
| Stephen J. Tulipano | Former CFO | $757,722 | 27 Mar 2024 | ||
| Huw M. Nash | Chief Business Officer | $631,200 | 02 Jul 2024 | ||
| Jason Hoitt | Chief Patient Officer | $497,273 | 15 Mar 2026 | ||
| Seth Loring Harrison | Director | 03 Jun 2025 | |||
| Julie Smith | Director | 03 Jun 2025 | |||
| Jennifer Burstein | Director | 03 Jun 2025 | |||
| ATP Life Science Ventures, L.P. | 10%+ Owner | 28 Jun 2021 | |||
| Garry E. Menzel | Director | 03 Jun 2025 | |||
| Ian F. Smith | Chief Executive Officer, Director | 17 Feb 2026 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jason Hoitt | STOK | Common Stock | Options Exercise | 250.8% | 10,000 | 13,988 | 15 Mar 2026 | Direct | ||
| Jason Hoitt | STOK | Restricted Stock Units | Options Exercise | -25% | -10,000 | 30,000 | 15 Mar 2026 | Direct | ||
| Thomas Leggett | STOK | Common Stock | Options Exercise | 14,750 | 14,750 | 15 Mar 2026 | Direct | |||
| Thomas Leggett | STOK | Restricted Stock Units | Options Exercise | -25% | -14,750 | 44,250 | 15 Mar 2026 | Direct | ||
| Barry Ticho | STOK | Common Stock | Options Exercise | 171% | 33,850 | 53,648 | 15 Mar 2026 | Direct | ||
| Barry Ticho | STOK | Restricted Stock Units | Options Exercise | -72.1% | -33,850 | 13,100 | 15 Mar 2026 | Direct | ||
| Edward M. Kaye MD | STOK | Common Stock | Options Exercise | 125.7% | 61,750 | 110,874 | 15 Mar 2026 | Direct | ||
| Edward M. Kaye MD | STOK | Restricted Stock Units | Options Exercise | -63.5% | -61,750 | 35,500 | 15 Mar 2026 | Direct | ||
| Jonathan Allan | STOK | Common Stock | Options Exercise | 207.9% | 25,475 | 37,731 | 15 Mar 2026 | Direct | ||
| Jonathan Allan | STOK | Restricted Stock Units | Options Exercise | -77.3% | -25,475 | 7,475 | 15 Mar 2026 | Direct | ||
| Arthur A. Levin | STOK | Common Stock | Sale | -12.5% | $22,264 | $36.80 | -605 | 4,237 | 13 Mar 2026 | Direct |
| Arthur Tzianabos | STOK | Common Stock | Sale | -12.2% | $174,214 | $40.00 | -4,355 | 31,339 | 10 Mar 2026 | Direct |
| Arthur Tzianabos | STOK | Common Stock | Options Exercise | 12.5% | 3,955 | 35,694 | 10 Mar 2026 | Direct | ||
| Arthur Tzianabos | STOK | Stock Option (Right to Buy) | Options Exercise | -3.22% | -3,955 | 118,696 | 10 Mar 2026 | Direct | ||
| Adrian R. Krainer | STOK | Common Stock | Sale | -10.5% | $1,320,964 | $39.74 | -33,243 | 283,302 | 10 Mar 2026 | Direct |
| Adrian R. Krainer | STOK | Common Stock | Sale | -2.23% | $286,715 | $39.66 | -7,229 | 316,545 | 02 Mar 2026 | Direct |
| Barry Ticho | STOK | Restricted Stock Units | Award | 40,000 | 40,000 | 17 Feb 2026 | Direct | |||
| Barry Ticho | STOK | Employee Stock Option (Right to Buy) | Award | 60,000 | 60,000 | 17 Feb 2026 | Direct | |||
| Ian F. Smith | STOK | Restricted Stock Units | Award | 129,000 | 129,000 | 17 Feb 2026 | Direct | |||
| Ian F. Smith | STOK | Employee Stock Option (Right to Buy) | Award | 193,000 | 193,000 | 17 Feb 2026 | Direct | |||
| Thomas Leggett | STOK | Restricted Stock Units | Award | 40,000 | 40,000 | 17 Feb 2026 | Direct | |||
| Thomas Leggett | STOK | Employee Stock Option (Right to Buy) | Award | 60,000 | 60,000 | 17 Feb 2026 | Direct | |||
| Jason Hoitt | STOK | Restricted Stock Units | Award | 48,000 | 48,000 | 17 Feb 2026 | Direct | |||
| Jason Hoitt | STOK | Employee Stock Option (Right to Buy) | Award | 72,000 | 72,000 | 17 Feb 2026 | Direct | |||
| Jonathan Allan | STOK | Restricted Stock Units | Award | 35,000 | 35,000 | 17 Feb 2026 | Direct | |||
| Jonathan Allan | STOK | Employee Stock Option (Right to Buy) | Award | 53,000 | 53,000 | 17 Feb 2026 | Direct | |||
| Arthur A. Levin | STOK | Common Stock | Options Exercise | 33.4% | 1,211 | 4,842 | 31 Dec 2025 | Direct | ||
| Arthur A. Levin | STOK | Restricted Stock Units | Options Exercise | -100% | -1,211 | 0 | 31 Dec 2025 | Direct | ||
| Jonathan Allan | STOK | Common Stock | Sale | -25.2% | $128,411 | $32.28 | -3,978 | 11,831 | 08 Dec 2025 | Direct |
| Edward M. Kaye MD | STOK | Common Stock | Sale | -21.5% | $433,385 | $32.27 | -13,430 | 49,124 | 08 Dec 2025 | Direct |
| Barry Ticho | STOK | Common Stock | Sale | -15.6% | $114,762 | $31.34 | -3,662 | 19,798 | 05 Dec 2025 | Direct |
| Edward M. Kaye MD | STOK | Common Stock | Sale | -12% | $267,761 | $31.32 | -8,548 | 62,554 | 05 Dec 2025 | Direct |
| Jonathan Allan | STOK | Common Stock | Sale | -35.7% | $274,898 | $31.29 | -8,785 | 15,809 | 05 Dec 2025 | Direct |
| Barry Ticho | STOK | Common Stock | Sale | -6.74% | $52,353 | $30.87 | -1,696 | 23,460 | 04 Dec 2025 | Direct |
| Edward M. Kaye MD | STOK | Common Stock | Sale | -8.32% | $199,197 | $30.87 | -6,453 | 71,102 | 04 Dec 2025 | Direct |
| Jonathan Allan | STOK | Common Stock | Sale | -3.97% | $31,425 | $30.87 | -1,018 | 24,594 | 04 Dec 2025 | Direct |
| Barry Ticho | STOK | Common Stock | Options Exercise | 66% | 10,000 | 25,156 | 03 Dec 2025 | Direct | ||
| Barry Ticho | STOK | Performance Stock Units | Options Exercise | -100% | -10,000 | 0 | 03 Dec 2025 | Direct | ||
| Edward M. Kaye MD | STOK | Common Stock | Options Exercise | 51.2% | 26,250 | 77,555 | 03 Dec 2025 | Direct | ||
| Edward M. Kaye MD | STOK | Performance Stock Units | Options Exercise | -100% | -26,250 | 0 | 03 Dec 2025 | Direct | ||
| Jonathan Allan | STOK | Common Stock | Options Exercise | 30.6% | 6,000 | 25,612 | 03 Dec 2025 | Direct | ||
| Jonathan Allan | STOK | Performance Stock Units | Options Exercise | -100% | -6,000 | 0 | 03 Dec 2025 | Direct | ||
| Barry Ticho | STOK | Common Stock | Sale | -11.7% | $61,725 | $30.65 | -2,014 | 15,156 | 03 Dec 2025 | Direct |
| Edward M. Kaye MD | STOK | Common Stock | Sale | -2.04% | $32,793 | $30.65 | -1,070 | 51,305 | 03 Dec 2025 | Direct |
| Jonathan Allan | STOK | Common Stock | Sale | -10.5% | $70,245 | $30.65 | -2,292 | 19,612 | 03 Dec 2025 | Direct |
| Barry Ticho | STOK | Common Stock | Sale | -10.5% | $59,743 | $29.78 | -2,006 | 17,170 | 02 Dec 2025 | Direct |
| Edward M. Kaye MD | STOK | Common Stock | Sale | -1.99% | $31,748 | $29.78 | -1,066 | 52,375 | 02 Dec 2025 | Direct |
| Jonathan Allan | STOK | Common Stock | Sale | -9.44% | $68,023 | $29.78 | -2,284 | 21,904 | 02 Dec 2025 | Direct |
| Barry Ticho | STOK | Common Stock | Options Exercise | 166.5% | 11,981 | 19,176 | 01 Dec 2025 | Direct | ||
| Barry Ticho | STOK | Restricted Stock Units | Options Exercise | -100% | -11,981 | 0 | 01 Dec 2025 | Direct |